|Featured Video : Banking on Cord Blood Stem Cells: Is the Future Here? |
Is banking cord blood akin to buying “car insurance” or “asteroid insurance”? Your questions are answered in this video from the recent World Stem Cell Summit. Along the way Dr. Mahendra Rao will describe some compelling business model options for the field. Support for this panel was provided by Cord Blood Registry.
Speakers include Heather Brown, MS, LCGC, Cord Blood Registry (moderator); Charles S. Cox, MD, UT Health Science Center at Houston; Mahendra Rao, MD, PhD, Q Therapeutics & NYSCF and Frances Verter, PhD, Parents Guide to Cord Blood Foundation.
The discussion provides updated information regarding preclinical and clinical experience with autologous stem cells for neurological applications and other potential future uses. Learning objectives include:
- Analyzing the potential role of cord blood stem cells as a promising therapeutic tool in the development of innovative treatments
- Explaining the current usage and therapeutic potential of cord blood stem cells
- Describing the use of autologous cord blood stem cells in clinical regenerative medicine applications
- Reviewing approaches for reprogramming cord blood cells into induced pluripotent stem cells and potential applications in regenerative medicine.
|The Guardian: UK MP’s vote in favor of 'three-person embryo' mitochondrial transfer law |
“MPs have voted in favor of making Britain the first country in the world to permit IVF babies to be created using biological material from three different people to help prevent serious genetic diseases. In a historic debate, the House of Commons voted by 382 to 128 – a majority of 254 – to allow mitochondrial donation through a controversial amendment to the 2008 Human Fertilisation and Embryology Act. They approved the regulation in spite of some critics warning it was a step towards creating ‘three-parent’ designer babies.” The New York Stem Cell Foundation (NYSCF) is doing groundbreaking mitochondrial research. Read its statement of support for the research here.
|Victoria (Australia) parliament approves therapeutic cloning legislation |
Victoria became the first Australian state to pass legislation allowing therapeutic cloning a/k/a somatic cell nuclear transfer or “SCNT” for stem cell production and research. “The new law allows excess human embryos from IVF treatment to be used to create stems cells for medical research. Health Minister Bronwyn Pike suggested that the law could spark a flood of medical research in the state.”
|The Townhall: U.S. Congressman to propose ‘Life at Conception Act' |
In contrast the Victoria legislation mentioned above, back here in the USA a social conservative lawmaker in Congress is proposing the ‘Life at Conception Act' that would implement protection for the right to life of each “born and preborn” human person. The bill cites the 14th Amendment as the means for protection. Sponsor of the bill is Representative Alex Mooney (R-W.Va.). The salient language of the bill states that, “The terms ‘human person’ and ‘human being’ include each and every member of the species homo sapiens at all stages of life, including the moment of fertilization, cloning, or other moment at which an individual member of the human species comes into being.”
360 Editor’s Note: Passage of this Draconian bill would largely eliminate hESCR and IVF treatments in the United States. The law would surely be unconstitutional. Initiatives like this are generally seen as a symbolic gambit to sway public opinion. Some social-conservative lawmakers are unrestrained in their efforts to curb this science and prop up support within their base of political support. Note that there are frequent battles of this type happening in some states. In Oklahoma this week, a bill to ban embryonic stem cell research passed in a key committee in the OK House.
|(Xinhua)- Sweden's Karolinska Institutet to set up regenerative medicine research base in Hong Kong |
This initiative is fueled by a donation of $50 million by Hong Kong-based businessman Ming Wai Lau. It is described as one of the largest private donations ever received by the Karolinska. The Ming Wai Lau Center for Regeneration Medicine will comprise two nodes, one in Stockholm and one in Hong Kong, and will allow scientists from Hong Kong, the mainland, and around the world to work together in an independent research environment under the auspices of the Karolinska Instituet. To learn more details about this unique collaboration, read the remarks of CY Leung, Chief Executive of Hong Kong. Click here.
|How we'll finally put an end to organ donation shortages |
Science journalist George Dvorsky writes in the io9 an interesting overview on the “here and now” of organ regeneration and cell printing. In related news, there is progress with the New Organ Liver Prize, a collective initiative for biomedical engineering and regenerative medicine. Two new teams have joined the field competing for the Prize, a global competition sponsored by the Methuselah Foundation, a biomedical charity. The prize challenge will award $1,000,000 to the first team that creates a regenerative or bioengineered solution that enables a large animal to live 90 days without native liver function. Read the details in the media release here.
|Now Playing: California’s $1 Billion stem-cell renovation show |
Xconomy’s Biotech Editor, Alex Nash, provides some revealing perspectives on the California Stem Cell Agency, that has profoundly and positively impacted the stem cell world in the last decade.
|Top RegMed visionary, Marie Csete,MD, PhD, named Huntington Medical Research Institute’s new president and chief scientist |
Dr. Csete is the former CSO of California Institute for Regenerative Medicine, California’s state stem cell agency, and Division Director of Cellular Therapies at AABB. She consulted for academics and industries developing regenerative medicine therapies, and continues to work on the improving standards for cellular therapies with the Foundation for the Accreditation of Cellular Therapies. Huntington Medical Research Institute (HMRI) based in Pasadena, California, is dedicated to enhancing knowledge of diseases in order to improve health and save lives. For more information, visit: http://www.hmri.org.
|Circle the date March 25- the Alliance for Regenerative Medicine (ARM) third annual Regen Med Investor Day |
The ARM Regen Med Investor Day will take place March 25, 2015 in New York City, co-hosted by the financial firm Piper Jaffray. The meeting features institutional, strategic and venture investors with insights into the financing hypothesis for advanced therapies-based treatments and technology.
|Lung fibosis- Cynata Therapeutics partners with UWA Centre for Cell Therapy and Regenerative Medicine |
According to a media release, stem cell and regenerative medicine company, Cynata Therapeutics Ltd (ASX: CYP), commenced a study to test the potential therapeutic efficacy of its mesenchymal stem cells (MSCs) in an animal model of lung fibrosis. This study will be performed within The University of Western Australia's Centre for Cell Therapy and Regenerative Medicine (CCTRM) in the School of Medicine and Pharmacology with researchers who have expertise in lung fibrosis and regenerative medicine.